Clinical Trials Logo

Filter by:
NCT ID: NCT03375203 Recruiting - Insomnia Disorders Clinical Trials

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

Start date: November 23, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document safety and tolerability of JNJ-42847922 upon multiple (14 days) dose administration in participants with insomnia disorder.

NCT ID: NCT03372837 Recruiting - Clinical trials for Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Start date: December 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.

NCT ID: NCT03372200 Not yet recruiting - Clinical trials for Hyperuricemia With or Without Gout

Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Start date: January 2018
Phase: Phase 3
Study type: Interventional

FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.

NCT ID: NCT03370913 Recruiting - Hemophilia A Clinical Trials

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients

BMN270-301
Start date: December 2017
Phase: Phase 3
Study type: Interventional

This clinical trial is being conducted to learn more about a potential treatment (valoctocogene roxaparvovec) for people with severe hemophilia A. This research study will test and confirm the safety and effectiveness of the 6E13 vg/kg dose of the study drug (valoctocogene roxaparvovec) that contains the correct gene to make Factor VIII so that the body can make its own Factor VIII that functions properly. Only one dose of valoctocogene roxaparvovec is being given in this study, and this dose has been previously studied in another clinical trial in patients with hemophilia A. This is a phase 3 study which is meant to show that the study drug is safe and works to help treat hemophilia A. The study will see if liver cells are able to make Factor VIII that functions properly after receiving this study drug. The study will also examine the effects that the study drug has on how much Factor VIII concentrates patients have to inject into their veins and on their bleeding episodes after the study drug has been administered. Finally, the study will see if and how the body responds to the study drug - for example, whether liver cells become inflamed or whether the body makes antibodies (something the immune system makes to protect itself against things like bacteria and viruses) against the vector or the new Factor VIII gene.

NCT ID: NCT03370640 Recruiting - Schizophrenia Clinical Trials

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

Start date: November 29, 2017
Phase: Phase 1
Study type: Interventional

This is a multiple oral dose, open-label study to assess the safety, tolerability, and pharmacokinetics of SEP-363856 in Japanese subjects with schizophrenia.

NCT ID: NCT03370302 Not yet recruiting - Clinical trials for Advanced Nonhematological Neoplasms

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Start date: January 15, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, recommended phase 2 dose (RP2D), and to characterize PK of TAK-228 administered once daily or once weekly to East Asian participants with advanced nonhematological malignancies.

NCT ID: NCT03370289 Recruiting - Clinical trials for Influenza Prevention

A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects

Start date: December 14, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of two intramuscular vaccinations with BLB-750 in healthy Japanese adults.

NCT ID: NCT03366818 Enrolling by invitation - Clinical trials for Acute Ischemic Stroke

New Stent Retriever, VERSI System for AIS

Start date: September 21, 2017
Phase: N/A
Study type: Interventional

To confirm efficacy and safety of VERSI system for acute ischemic stroke

NCT ID: NCT03364751 Recruiting - Clinical trials for Chronic Periodontitis

Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome

Start date: November 7, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate in patients with generalized chronic periodontitis that switching from cigarette smoking to using IQOS improves the response to periodontal therapy and the overall oral health status compared to continuing cigarette smoking. Note: "IQOS" is the Tobacco Heating System (THS) with Marlboro Heatsticks, marketed in Japan under the brand name IQOS

NCT ID: NCT03364244 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Revavtio Special Investigation for Long-term Use in Pediatric Patients

Start date: November 30, 2017
Phase: N/A
Study type: Observational

Secondary data collection study: safety and effectiveness of Revatio in pediatric patients under Japanese medical practice